Profile
| Metric | Value |
|---|---|
| Full Name | Roivant Sciences Ltd. |
| Ticker | NASDAQ: ROIV |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United Kingdom |
| IPO | |
| Indexes | Not included |
| Website | roivant.com |
| Employees | 750 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $23.81 | |
| Price, 1D Change | +1.58% | |
| Market Cap | $17B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.74 | |
| Revenue | $29M | |
| Revenue, 1Y Change | -11.19% | |
| EPS | -$0.24 | |
| EPS, 1Y Change | -104.53% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$0.24 | |
| EPS Estimate | N/A | -$1.09 |
| EPS Est. Change | N/A | -361.24% |
| Revenue | $29.05M | |
| Revenue Estimate | N/A | $15.94M |
| Revenue Est. Change | N/A | -45.13% |
| Current Price | $23.81 | |
| Price Target | - | $26.00 |
| Price Tgt. Change | - | +9.20% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.27 | $5.23 | +22.56% | |
| -$0.57 | -$0.24 | +58.40% | |
| -$1.09 | N/A | -361.24% | |
| -$1.13 | N/A | -377.69% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $144.79M | $32.71M | -77.41% | |
| $141.31M | $29.05M | -79.44% | |
| $15.94M | N/A | -45.13% | |
| $118.13M | N/A | +306.60% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +117.64% | |
| Price, 3Y | +141.24% | |
| Market Cap, 1Y | +110.34% | |
| Market Cap, 3Y | +130.84% | |
| Revenue, 1Y | -11.19% | |
| Revenue, 3Y | -47.45% | |
| EPS, 1Y | -104.53% | |
| EPS, 3Y | +81.21% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $23.81 | |
| SMA 200 | $14.69 | |
| SMA 200 vs Price | -38.32% | |
| SMA 50 | $21.30 | |
| SMA 50 vs Price | -10.56% | |
| Beta | 0.74 | |
| ATR | $0.76 | |
| 14-Day RSI | 69.00 | |
| 10-Day Volatility | 34.71% | |
| 1-Year Volatility | 32.76% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $29.05M | |
| EPS | -$0.24 | |
| Gross Profit | $20.81M | |
| Gross Margin | 71.63% | |
| Operating Profit | -$1.11B | |
| Operating Margin | -3,861.65% | |
| Net Income | -$729.76M | |
| Net Margin | -2,511.84% | |
| EBITDA | -$1.11B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.02 | |
| Current Ratio | 33.47 | |
| Quick Ratio | 33.47 | |
| - | ||
| F-Score | 3 | |
| Altman Z-Score | 40.21 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 814.58 | |
| PB Ratio | 3.80 | |
| EV/EBITDA | -10.72 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $4.69B | |
| Cash & Equivalents | $4.89B | |
| Total Assets | $5.44B | |
| Current Assets | $5.00B | |
| Total Liabilities | $249.74M | |
| Current Liabilities | $149.41M | |
| Total Debt | $100.17M | |
| Short Term Debt | $9.84M | |
| Accounts Payable | $23.69M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $574.06M | |
| Operating Expenses | $1.13B | |
| Cost Of Goods Sold | $8.24M | |
| SG&A | $0.00 | |
| D&A | $7.33M | |
| Interest Expense | $0.00 | |
| Income Tax | $48.17M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$839.45M | |
| CFI | -$1.77B | |
| CFF | -$1.22B | |
| Capex | $4.60M | |
| Free Cash Flow | -$844.05M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Leerink Partners | → | |
| Goldman Sachs | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| Citigroup | → | |
| Leerink Partners | → | |
| Jefferies | → | |
| JP Morgan | → | |
| HC Wainwright & Co. | → | |
| Guggenheim | → |
Analyst sentiment
Institutional ownership
Screeners with ROIV
Data Sources & References
- ROIV Official Website roivant.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1635088/000163508825000016/0001635088-25-000016-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1635088/000114036125020715/0001140361-25-020715-index.htm
- ROIV Profile on Yahoo Finance finance.yahoo.com/quote/ROIV
- ROIV Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/roiv
FAQ
What is the ticker symbol for Roivant Sciences Ltd.?
The ticker symbol for Roivant Sciences Ltd. is NASDAQ:ROIV
Does Roivant Sciences Ltd. pay dividends?
No, Roivant Sciences Ltd. does not pay dividends
What sector is Roivant Sciences Ltd. in?
Roivant Sciences Ltd. is in the Healthcare sector
What industry is Roivant Sciences Ltd. in?
Roivant Sciences Ltd. is in the Biotechnology industry
What country is Roivant Sciences Ltd. based in?
Roivant Sciences Ltd. is headquartered in United Kingdom
When did Roivant Sciences Ltd. go public?
Roivant Sciences Ltd. initial public offering (IPO) was on December 8, 2020
Is Roivant Sciences Ltd. in the S&P 500?
No, Roivant Sciences Ltd. is not included in the S&P 500 index
Is Roivant Sciences Ltd. in the NASDAQ 100?
No, Roivant Sciences Ltd. is not included in the NASDAQ 100 index
Is Roivant Sciences Ltd. in the Dow Jones?
No, Roivant Sciences Ltd. is not included in the Dow Jones index
When was Roivant Sciences Ltd. last earnings report?
Roivant Sciences Ltd.'s most recent earnings report was on November 10, 2025
When does Roivant Sciences Ltd. report earnings?
The next expected earnings date for Roivant Sciences Ltd. is February 9, 2026